Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$112.85
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | GILD Avg Daily Volume: 11,081,400
Last Update: 05/28/15 - 3:59 PM EDT
Volume: 0
YTD Performance: 19.72%
Open: $0.00
Previous Close: $112.85
52 Week Range: $78.50 - $116.83
Oustanding Shares: 1,469,605,980
Market Cap: 165,271,888,511
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 11 12
Moderate Buy 3 3 2 2
Hold 2 2 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.59 1.56 1.65 1.61
Latest Dividend: 0.43
Latest Dividend Yield: 1.53%
Dividend Ex-Date: 06/12/15
Price Earnings Ratio: 12.81
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
12.81 12.80 26.97
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.00% 37.86% 347.02%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $2.83 $2.72 $11.04 $9.56
Number of Analysts 1 1 1 1
High Estimate $2.83 $2.72 $11.04 $9.56
Low Estimate $2.83 $2.72 $11.04 $9.56
Prior Year $2.32 $1.79 $7.91 $11.04
Growth Rate (Year over Year) 21.98% 51.96% 39.57% -13.41%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Sector may not be as bulletproof as we thought.
Buy at right price and have courage to hold.
And we're off! Not surprisingly given the (lack of) action in the market this week, the main indices are roughly flat across the board in early going. Biotech seems to be showing some strength. Gilead Sciences (GILD) continues its recent well-deserved winning streak, with its shares at their highest 2015 levels. Even with this rally, the stock goes for just over 10x this year's projected earnings -- and the consensus earnings estimates continue to go up.
Although I believe the overall market is overbought, there are still a few values to be had.
Acquisitions cut into overabundance of companies.
Many of these stocks are off to the races.
You could throw darts at financials and health care and win. 
Some companies are so strong that they buck the rotation.
Remember that rotations are vicious.

Columnist Conversations

http://www.wsj.com/articles/moodys-upgrades-four-top-u-s-banks-1432855260
This is important news - and it is not market constructive. It is a conclusion that is consistent with my last...
A "mega car merger" is being discussed on Fast Money tonite. The shares are trading up in after hours trading....
All better than expected!!

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.